Targeting Investigation and Treatment in Type 2 Myocardial Infarction: A Pilot Randomized Controlled Trial
Authors' conclusion
It is feasible to recruit and randomize patients with type 2 myocardial infarction to a complex intervention targeting coronary or structural heart disease. A multicenter trial with an optimized intervention is now required to inform practice.
Study context
- Population
- Patients with type 2 myocardial infarction (increased cardiac troponin concentrations screened)consented and randomized, 4,127 screened, 403 met inclusion criteria, 143 eligible, 119 approached
- Participants
- 60 patients
- Comparison
- Complex intervention of investigation and treatment for coronary and structural heart disease vs standard care
- Interventionn = 28
- Standard caren = 32
Methodological details3 sites, qualitative interviews
- 3 sites
- Qualitative interviews
Further findings
Recruitment process · November 2022 and November 2023
- Screened
- 4,127
- Met inclusion criteria
- 403 patients (10%)
- Eligible
- 143 patients (35%)
- Approached (of those eligible)
- 119 patients (83%)
- Consented and randomized
- 60 patients (42%
- Follow-up was complete in all participants.
Adherence to recommendations · 90 days
- Adherence to recommendations
- 90.7% (95% CI: 85.3%-96.1%)
Qualitative interviews
- Variation in communication of the diagnosis and in trial investigation and management recommendations were potential barriers to participation
Original publication
Targeting Investigation and Treatment in Type 2 Myocardial Infarction: A Pilot Randomized Controlled Trial. JACC Adv. Published 4 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →